Mainz Biomed in new Strategic Advisory Board appointment

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Rainer Metzger to its Strategic Advisory Board.

“We’re thrilled to welcome Rainer who brings our Strategic Advisory Board significant senior level commercial experience within the field of oncology diagnostics,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “He will play a key role, supporting the Company’s clinical and commercial expansion through introductions to strategic commercial partners and exploration of global distribution relationships as we continue to execute on our business model and expand our market penetration through partnering with leading third-party laboratories across multiple territories.”

Dr. Metzger is a global business executive and operations leader with almost three decades of executive experience within the life science and healthcare sector with global pharmaceutical and diagnostics companies including ROCHE, DANAHER and QIAGEN. During his close-to ten-year career with Roche, Dr. Metzger held several VP roles leading highly-successful global business development and clinical biomarker programs within oncology and corporate and molecular diagnostics. As Roche’s VP, Global Head Business and Biomarker Operations and Biosample and Repository Management, his span of influence included the development of the Pharma Biomarker Personalized Healthcare initiative, and the implementation and delivery of a highly-valuable technology/product portfolio with several hundred individual biomarker programs. As VP, Head of Global Business Development and Strategic Marketing Oncology, he led a multifunctional BD and marketing team developing and executing Roche’s global brand strategy for oncology.

During his multi-year, executive tenure with worldwide provider of molecular sample and assay technologies, QIAGEN, as global department head within diagnostics and pharmaceuticals, Dr. Metzger led business development and drove partnership programs for various disease areas, contributing 20-30% of annual growth through the initiation and execution of master collaboration agreements with the majority of the top 50 global pharma companies.

“I have been exceptionally impressed by what has already been achieved at Mainz Biomed,” said Dr. Metzger. “The ColoAlert test provides superior accuracy and simplicity over current incumbent Colorectal Cancer screening methods and having successfully led business development strategies for multiple new and pioneering diagnostic solutions throughout my career, I’m excited to use my experience to help ColoAlert take a prominent role in the global fight against colorectal cancer.”